Rapid development of a synthetic DNA vaccine for COVID-19
Author:
Smith Trevor R.F.1, Patel Ami2, Ramos Stephanie1, Elwood Dustin1, Zhu Xizhou2, Yan Jian1, Yang Maria1, Chokkalingam Neethu2, Gary Ebony N.2, Schultheis Katherine1, Pezzoli Patrick1, Walters Jewell1, Walker Susanne N.2, Parzych Elizabeth2, Reuschel Emma L.2, Doan Arthur1, Tursi Nicholas2, Vasquez Miguel1, Choi Jihae2, Maricic Igor1, Bah Mamadou A.2, Wu Yuanhan2, Amante Dinah1, Park Daniel2, Dia Yaya2, Ali Ali Raza2, Zaidi Faraz I.2, Generotti Alison1, Kim Kevin Y.2, Herring Timothy A.1, Reeder Sophia2, Brown Ami Shah1, Khoshnejad Makan2, Wang Nianshuang3, Chu Jacqueline2, Wrapp Daniel3, McLellan Jason S3, Muthumani Kar2, Kim J Joseph1, Boyer Jean1, Kulp Daniel W.2, Humeau Laurent M.P.F.1, Weiner David B.2, Broderick Kate E.1
Affiliation:
1. Inovio Pharmaceuticals, Plymouth Meeting, PA 2. Vaccine and Immunotherapy Center, Wistar Institute 3. Department of Molecular Biosciences, The University of Texas at Austin
Abstract
Abstract
The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for the outbreak of viral pneumonia disease, COVID-19 which first emerged in mid-December 2019 in the city of Wuhan in central China. As of February 25, 2020 there are 80,994 people infected and 2,760 deaths, and documented human-to-human transmission across multiple continents. At this time, no vaccine is available to control further dissemination of the disease. We have previously developed a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein that was deployed in response to the MERS outbreak in South Korea. This vaccine induced potent antibody and CTL responses, and provided protection in a NHP challenge model. In the clinic, the vaccine generated humoral immunity including neutralizing antibody responses, as well as T cell immunity. Here we build on this prior work and report on the rapid development of a synthetic DNA-based vaccine targeting the major surface antigen Spike protein of SARS-CoV-2. The engineered construct, INO-4800 induced robust expression of the Spike protein in vitro, and generated antibody and T cell responses following a single immunization in mice and guinea pigs. This preliminary dataset identifies INO-4800 as a potential COVID-19 vaccine candidate, supporting further study for mobilization against this emerging disease threat.
Publisher
Research Square Platform LLC
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|